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size in the cerebellum was found to correlate with disease 
duration. Somatic heterogeneity suggests there is a degree 
of instability within the repeat and evidence of anticipation 
has been reported with reducing age of onset in subsequent 
generations. This variability/instability in expansion length, 
along with its interactions with environmental and genetic 
modifiers, such as TMEM106B, may be the basis of the dif-
fering clinical phenotypes arising from the mutation.
Keywords Amyotrophic lateral sclerosis · 
Frontotemporal lobar dementia · C9ORF72 · G4C2 
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Introduction
One of the most interesting features of hexanucleotide 
repeat expansions of C9ORF72 is that the associated phe-
notype is extremely variable and indeed, except in certain 
pedigrees, the expansion does not appear to be 100 % 
penetrant [1]. Although it was discovered in patients with 
amyotrophic lateral sclerosis (ALS) and/or frontotemporal 
lobar degeneration (FTLD) [2, 3] many of the original stud-
ies of cohorts of C9ORF72-related patients noted the pres-
ence of other clinical phenotypes in probands and family 
members, at higher frequencies than would be expected by 
chance [4]. For the purposes of this review, clinical pres-
entations will be divided into motor and non-motor pheno-
types within which various recognised symptom complexes 
will be discussed (Fig. 1). The variability in, and indeed 
within, clinical presentations of C9ORF72-related disease 
[4] is a source of hope as well as a challenge as it suggests 
that multiple disease modifiers are at work, each of which 
is a potential therapeutic target. Understanding what these 
potential modifiers might be is at an early stage and indeed 
Abstract The GGGGCC (G4C2) repeat expansion in 
C9ORF72 is the most common cause of familial amyo-
trophic lateral sclerosis (ALS), frontotemporal lobar 
dementia (FTLD) and ALS–FTLD, as well as contrib-
uting to sporadic forms of these diseases. Screening of 
large cohorts of ALS and FTLD cohorts has identified that 
C9ORF72-ALS is represented throughout the clinical spec-
trum of ALS phenotypes, though in comparison with other 
genetic subtypes, C9ORF72 carriers have a higher inci-
dence of bulbar onset disease. In contrast, C9ORF72-FTLD 
is predominantly associated with behavioural variant FTD, 
which often presents with psychosis, most commonly in the 
form of hallucinations and delusions. However, C9ORF72 
expansions are not restricted to these clinical phenotypes. 
There is a higher than expected incidence of parkinsonism 
in ALS patients with C9ORF72 expansions, and the G4C2 
repeat has also been reported in other motor phenotypes, 
such as primary lateral sclerosis, progressive muscular 
atrophy, corticobasal syndrome and Huntington-like disor-
ders. In addition, the expansion has been identified in non-
motor phenotypes including Alzheimer’s disease and Lewy 
body dementia. It is not currently understood what is the 
basis of the clinical variation seen with the G4C2 repeat 
expansion. One potential explanation is repeat length. Siz-
ing of the expansion by Southern blotting has established 
that there is somatic heterogeneity, with different expansion 
lengths in different tissues, even within the brain. To date, 
no correlation with expansion size and clinical phenotype 
has been established in ALS, whilst in FTLD only repeat 
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the number of likely modifiers means that large numbers of 
cases are going to be needed to illustrate any single effect. 
The most obvious potential modifier is expansion size, but 
as yet a clear relationship has not been established in ALS, 
although there is more indication of a correlation with phe-
notype in FTLD.
The penetrance of C9ORF72-related disease does not 
appear to differ between ALS and FTLD pedigrees. Iden-
tification of repeat expansions in the general population 
during mutation screening of neurologically normal con-
trols [1, 4] suggests that C9ORF72 expansions may actu-
ally be as common in “controls” as in specific clinical 
phenotypes, such as corticobasal syndrome (CBS) and 
sporadic Creutzfeldt–Jakob disease [1, 5]. It has been sug-
gested that these C9ORF72 “controls” might represent pre-
symptomatic disease as estimates suggest that C9ORF72 
expansions are non-penetrant at <35 years, 50 % penetrant 
by 58 years and fully penetrant at 80 years [5, 6]. Alter-
natively, the penetrance of the expansion may not reach 
100 % even at 80 years, as others have reported C9ORF72 
expansion carriers aged 80 years and over without a clini-
cal phenotype [7]. This implies that the expansions in Alz-
heimer’s disease cases may be chance occurrences. Based 
on estimates of prevalence of ALS and FTLD in the UK 
population being 0.3 and 0.07 %, respectively [8, 9] and the 
proportion of cases with C9ORF72 expansions being 10 % 
for ALS and 13.6 % for FTLD [5], we have calculated the 
lifetime risk of C9ORF72-related disease to be approxi-
mately 0.04 %. There is, therefore, a 15-fold difference 
between the estimated frequency of C9ORF72 repeat 
expansions in controls of up to 0.6 % [4], and the lifetime 
risk of C9ORF72-related disease. This difference is perhaps 
too large to be explained by premature death of expansion 
carriers from other causes, although this remains to be veri-
fied. The variable penetrance also raises the possibility that 
C9ORF72 expansions may be a risk factor for disease and 
may not be capable of producing disease in isolation. There 
is a higher than expected coincidence of repeat expansions 
found in individuals carrying other genetic variants of 
ALS, so-called oligogenic inheritance [10], suggesting that 
another ‘hit’ may be necessary for clinical disease. Oligo-
genic inheritance has also been reported in FTLD, with the 
C9ORF72 expansion being identified in patients carrying 
GRN mutations [11, 12].
C9ORF72 in ALS and other motor phenotypes
Epidemiology
Whilst the majority of cases of ALS are sporadic, data 
show that 5–10 % of ALS cases show clear autosomal 
dominant inheritance [13], whilst twin studies estimate 
that the genetic heritability of disease is between 0.38 and 
0.78 [14]. Over 20 loci have been identified, with the genes 
identified at 17, the most common causes being mutations 
of C9ORF72, SOD1, TARDBP and FUS [15].
Screening for the C9ORF72 expansion in ALS cohorts 
worldwide has identified this mutation as the most com-
mon genetic cause of ALS in Caucasians, and the pro-
portion of patients affected is significant in this com-
plex neurodegenerative disease. In the Northern England 
population, C9ORF72 expansions are present in 43 % of 
ALS cases with an identifiable family history and in 7 % 
of apparently sporadic cases [4]. However, this frequency 
varies globally: C9ORF72 expansions were found in 
61 % of familial ALS and 19 % of sporadic ALS patients 
in Finland [5], 22 % of familial ALS cases in Germany 
[5] and only 3.4 % in Japan [16]. The apparent correla-
tion of expansion frequency with distance from Scandina-
via is consistent with a suggested common founder rather 
than repeated de novo occurrence. Indeed the C9ORF72 
expansion was identified through study of a risk haplo-
type at the 9p21 locus [17]. Following the screening of 
numerous populations for the C9ORF72 expansion, it has 
been shown to occur in the presence of the same haplo-
type in all populations considered, or with the A-allele of 
rs389942, which is associated with the haplotype [18], 
including populations which might be considered rela-
tively genetically different from Scandinavia such as Japan 
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Fig. 1  Clinical phenotypes associated with G4C2 repeat expansion 
of C9ORF72: both motor and non-motor phenotypes are associated 
with C9ORF72 expansions. The primary phenotype in each case is 
amyotrophic lateral sclerosis (ALS) and frontotemporal lobar demen-
tia (FTLD). Other phenotypes have been noted in very small numbers 
of patients: motor phenotypes in this group are parkinsonism, olivo-
pontocerebellar degeneration, corticobasal syndrome and Hunting-
ton’s disease phenocopies. The only non-motor phenotype identified 
in more than a few individuals is Alzheimer’s disease
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[16]. Data analysis of a 42-SNP haplotype from carriers 
of the expansion in Europe, USA and Australia led to the 
hypothesis that there was a common founder carrying the 
pathogenic mutation approximately 100 generations ago in 
Northern Europe and this expansion then spread across the 
world [5]. A European study using an 82-SNP haplotype 
suggests the expansion is much older, with the common 
founder arose over 251 generations ago [19]. As the dis-
ease has a late age of onset, this means it is not subject to 
reproductive pressure. However, other studies have contra-
dicted the founder effect, showing no evidence of recent 
shared ancestry in cases identified within the South-east 
region of the UK and the presence of the expansion in a 
patient homozygous for the non-risk G-allele [1, 20].
The origin of the expansion becomes even more 
intriguing if it is considered whether it is the expansion 
itself or a propensity for the region to expand that is inher-
ited. One of the initial studies of C9ORF72 noted that the 
risk haplotype was associated with an increased number 
of repeats even in controls [3]. It was determined, in a 
group of controls, that longer repeat lengths were associ-
ated with the rs389942 A-allele and that over 10 repeats 
was associated with inter-generational changes in repeat 
length [1].
C9ORF72-related ALS phenotypes
ALS is a neurodegenerative disease defined clinically as 
the loss of upper and/or lower motor neurons. It is a disease 
of ageing: peak age of onset is between 50 and 70 years 
[21]. Progression is relentless and death usually results 
from respiratory failure, between 3 and 5 years after onset 
of symptoms [22]. However, the ALS phenotype is notably 
variable; approximately 20 % of patients survive longer 
than 5 years [23] and cases have been reported in teenagers 
and the very elderly. The disease usually starts in one area 
and spreads in an anatomically contiguous fashion through-
out the motor system [24]. Typically this involves insidious 
progression of weakness from one limb or the bulbar mus-
cles; rarely does the disease simultaneously start in multi-
ple areas or in the respiratory muscles.
Broadly, the ALS phenotype associated with G4C2 repeat 
expansion of C9ORF72 is representative of the whole 
clinical spectrum of ALS [4, 25, 26]. However, within the 
broad range of phenotypes, bulbar onset has been found 
to be more frequently associated with C9ORF72-related 
ALS, than with non-C9ORF72 ALS [4, 27–29]; and as 
would be expected from the association of C9ORF72 
with FTLD, there is a greater incidence of dementia or a 
family history of dementia in C9ORF72-related ALS, 
than in non-C9ORF72 ALS [4, 25, 29–32]. In addition, 
there is evidence of an earlier age of onset in C9ORF72-
related ALS compared to non-C9ORF72 ALS cases [30, 
31] though not all cohorts reached significance [4, 31]. 
However, in a Belgian cohort, where specifically familial 
cases with C9ORF72-related ALS were compared to non-
C9ORF72 familial ALS cases, the age of onset was later 
in C9ORF72-related familial ALS [27]. In contrast, there 
were no differences between C9ORF72-related and non-
C9ORF72 sporadic ALS cases. Finally, evidence suggests 
that C9ORF72-related ALS has a shorter survival than 
non-C9ORF72 ALS [4, 27–32]. Some of the discrepan-
cies between these reports may be explained by different 
cohorts being used in the comparisons (e.g. all C9ORF72-
related ALS v all non-C9ORF72 ALS as opposed to famil-
ial C9ORF72-related ALS v familial non-C9ORF72 ALS) 
and due to the extensive variability in the non-C9ORF72 
ALS phenotype. However, gender may also play a role as 
male C9ORF72-related ALS cases have been reported to 
have a younger age of onset than non-C9ORF72 ALS cases 
[33].
To address the variability of non-C9ORF72 ALS, one 
study compared a large cohort of C9ORF72-related ALS 
cases directly with patients carrying other genetic vari-
ants [34]. This showed that C9ORF72-related cases had a 
significantly higher incidence of bulbar onset compared to 
ALS cases with mutations in SOD1, TARDBP, FUS and 
other familial ALS cases, as well as a greater association 
with FTLD. Disease duration of C9ORF72-related ALS 
was significantly shorter than in patients with mutations 
in SOD1, TARDBP or other familial ALS cases, but did 
not differ from FUS cases, whilst there was an older age 
of onset in C9ORF72-related ALS compared to SOD1 and 
FUS-related ALS, but not when compared with TARDBP 
and other familial ALS cases.
Other motor phenotypes
Parkinsonism
What is most clear about the C9ORF72-related ALS phe-
notype compared to other ALS cases, whether familial or 
sporadic, is an association with other neurological pheno-
types both motor and extramotor [4, 34]. Most prominently 
this includes FTLD and a number of other non-motor 
phenotypes (which will be discussed further in the sec-
tion on “FTLD and other dementia and psychosis-related 
phenotypes”). In addition to FTLD, we and others also 
noted an association with other motor phenotypes includ-
ing parkinsonism; by which we refer to the clinical pres-
entation rather than confirmed Parkinson’s disease (PD) 
with α-synucleinopathy. It is clear that parkinsonism is 
over-represented compared to chance in C9ORF72-related 
ALS cases and their families [3, 4, 35, 36]. Despite this, a 
number of studies have failed to find C9ORF72 expansions 
in patients with a clinical diagnosis of pure PD [37–39] or 
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only very rarely and often in patients with a family history 
of ALS/FTLD [40, 41] perhaps suggesting a pathogenesis 
distinct from classical idiopathic PD. Focusing on the neu-
ropathology of these cases, added some clarity to this point. 
Whilst there was no evidence for over-representation of 
C9ORF72 expansions in a cohort of PD patients with con-
firmed α-synucleinopathy, neurodegeneration was shown in 
the substantia nigra of C9ORF72-related ALS cases [40]. 
Therefore, it is suggested that whilst C9ORF72 expansions 
are not a cause of classical PD, the neuropathology associ-
ated with C9ORF72-related ALS can affect the substantia 
nigra and cause parkinsonism. Thus, C9ORF72 expansions 
can affect multiple brain areas which lead to different clini-
cal consequences.
Multiple sclerosis
Another phenotype associated with C9ORF72-related ALS 
was demyelination [4]. To further investigate this, a cohort 
of multiple sclerosis (MS) cases was screened but no 
C9ORF72 expansions were identified. However, in a small 
number of prospectively identified cases with MS who sub-
sequently developed ALS, there was a significantly higher 
than expected number of C9ORF72 expansions [42]. Rather 
than C9ORF72 expansions causing MS it is suggested MS 
increased the penetrance of the C9ORF72 expansion, and 
this was supported by the fact that C9ORF72-related ALS 
was more rapidly progressive in the patients with a previ-
ous history of MS.
Other motor phenotypes screened or associated with for 
C9ORF72 expansions
With the widening clinical phenotypes associated with 
ALS, several other neurodegenerative disease cohorts have 
been screened to determine if they are associated with the 
C9ORF72 repeat expansion. Whilst ALS is defined as the 
loss of both upper and lower motor neurons, primary lateral 
sclerosis (PLS) is characterised by the degeneration of only 
upper motor neurons whilst the loss of only lower motor 
neurons is defined as progressive muscular atrophy (PMA). 
These three disorders are considered to form part of a spec-
trum of disease. However, screening for the C9ORF72 
expansion found the expanded repeats at relatively low fre-
quencies in the PMA and PLS cohorts, at 1.6 and 0.9 %, 
respectively [43], and in a smaller cohort of PMA, PLS 
and progressive bulbar palsy patients, no expansions were 
found [44]. Thus, C9ORF72 expansions appear to be more 
commonly associated with an ALS phenotype within this 
spectrum of disease.
Hereditary spastic paraplegia (HSP) describes a group of 
over 50 genetically heterogeneous diseases which are char-
acterised by a progressive dying back of the distal axons 
of upper motor neurons, leading to lower limb spasticity, 
pyramidal distribution weakness in the lower limbs and 
brisk reflexes. To establish if C9ORF72 might be a modifier 
of the HSP phenotype, a Danish cohort of 182 HSP cases 
was screened for the repeat expansion [45]. However, no 
mutations were identified. The mutation was not associated 
with any cases of corticobasal syndrome or progressive 
supranuclear palsy (PSP) in Italy or the United States [46, 
47] but was identified in a Danish patient with CBS [48]. 
In addition, where ALS + CBS and ALS + PSP were the 
clinical diagnosis, C9ORF72 expansions were identified 
[49]. Finally, a pathological characterisation of C9ORF72-
FTLD cases identified an individual with FTLD-tau and 
corticobasal degeneration [50].
In the Danish cohort of dementia cases, which included 
the C9ORF72-related CBS case, C9ORF72 expansions 
were also found in one patient clinically diagnosed with 
olivopontocerebellar degeneration (OPCD) (where his 
father had ALS) and one patient with atypical Parkinso-
nian syndrome (APS) [48]. The range of motor pheno-
types associated with C9ORF72 expansions was widened 
further with expansions found in multiple cases of a cohort 
of Huntington disease-like syndromes and “other neurode-
generative diseases” (excluding ALS and FTLD) [1]. The 
association of C9ORF72 with HD-like symptoms was sup-
ported by 1.95 % cases within a cohort of HD phenocopies 
being positive for the expansion [51]. Thus, the C9ORF72 
expansion is associated with additional motor phenotypes, 
outside of the ALS spectrum, albeit at low frequencies.
C9ORF72 in FTLD and other dementia 
and psychosis‑related phenotypes
Epidemiology
Whilst the majority of cases of FTLD are sporadic, a body 
of evidence shows that approximately 13 % of FTLD cases 
show clear autosomal dominant inheritance. However, up 
to 40 % of cases have an additional member of the fam-
ily with the disease, though whether this is a contribution 
of genes or environment or both remains to be established 
[52].
Mutations in MAPT, CHMP2B, VCP, GRN, TARDBP 
and FUS have been previously published as genetic causes 
of autosomal dominant FTLD. However, with the iden-
tification of the C9ORF72 repeat expansion as a cause of 
FTLD and ALS–FTLD [2, 3], many cohorts of FTLD cases 
have been screened to establish the frequency of this gene 
in FTLD. A consistent finding is that the C9ORF72 expan-
sion is the most frequent mutation associated with famil-
ial cases, accounting for 25.1 % of familial FTLD [5]. In 
addition, the C9ORF72 mutation is also found in 6 % of 
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sporadic FTLD cases, though there is a wide variation in 
frequency across different populations, with the highest 
frequencies in geographically isolated populations such as 
Finland (21 %) [53] and the lowest frequency found in Hol-
land (2.2 %) [5]. The mutation is most frequently found in 
Caucasian populations, although the expansion has recently 
been shown in two Chinese cases, one with sporadic FTLD 
and another with familial ALS–FTLD [54]. This is in con-
trast to ALS, where C9ORF72 carriers are seen in Native 
American, Hispanic, Middle Eastern and Asian populations 
[5].
As discussed earlier, the expansion is suggested to have 
arisen over 100 generations ago in Northern Europe, based 
upon analysis that suggested expansion carriers all carried 
the same risk haplotype [5]. However, as with ALS, this is 
not always the case [11]. Ferrari and colleagues report four 
cases which carried the surrogate risk haplotype marker 
rs3849942 A-allele, but did not carry the complete 42 SNP 
risk haplotype. This finding is most likely to be due to the 
ethnically diverse background of these patients from the 
USA and the effect of recombination events throughout the 
preceding generations.
In addition, what is particularly interesting about the 
chromosome 9p21 region is that if expansion carriers are 
excluded, the locus still shows significant linkage to the 
ALS phenotype, suggesting a further genetic risk factor 
may be associated with the same region. This may perhaps 
point to the presence of another expansion [55]. Further 
sequencing and analysis of the region will be required to 
elucidate the basis of this linkage finding.
C9ORF72-related FTLD phenotypes
FTLD is the second most common form of degenerative 
dementia after Alzheimer’s disease to occur in individuals 
younger than 65 years old, and accounts for 5–15 % of all 
dementia cases. Survival is on average 7 years from onset. 
It can be subdivided according to the presenting features 
into behavioural variant FTLD (bvFTLD), where there is a 
change in the patients behaviour associated with a progres-
sive deterioration of personality, usually beginning with 
hallucinations, delusions, disordered thinking or paranoia, 
or primary progressive aphasia (PPA). PPA can be further 
subdivided into progressive non-fluent aphasia (PNFA) 
where patients have difficulties with word retrieval, non-
fluent speech patterns and a progressive loss of speech, and 
semantic dementia (SD), where there is a loss of memory 
regarding the understanding of words and objects. In addi-
tion, FTLD can be associated with extrapyramidal move-
ment disorders, such as parkinsonism or corticobasal 
syndrome as well as amyotrophic lateral sclerosis/motor 
neurone disease (FTLD–ALS/FTLD–MND), which will be 
discussed later.
The predominant FTLD phenotype associated with 
C9ORF72 mutations is that of bvFTLD. The high inci-
dence of this variant in the C9ORF72 expansion carriers 
was reported in the initial publications [2, 3]. Subsequent 
screening of FTLD cohorts across the UK, Europe, Amer-
ica and Australia identified bvFTLD as consistently more 
prevalent in C9ORF72-related FTLD than non-C9ORF72 
FTLD cases [6, 11, 20, 25, 26, 35, 46, 47, 53, 56–60]. The 
percentage of bvFTLD within C9ORF72-related FTLD 
varied within the cohorts, but it was always higher by 
12–19 % [6, 53, 59]. Within the C9ORF72 bvFTLD cases 
there were a significant number who presented with psy-
chosis, most commonly hallucinations and delusions [47, 
59]. This is exemplified in a UK study where a third of the 
C9ORF72-related FTLD cases presented with psychosis, 
compared to only 4 % in the non-C9ORF72 cases [59]. 
Whilst bvFTLD was the most common FTLD variant asso-
ciated with C9ORF72 expansion, PNFA was the second 
most common FTLD variant associated with C9ORF72 
expansions, although the frequency of PNFA did not differ 
between carriers and non-carriers of the expansion. SD has 
been seen more rarely associated with C9ORF72 expan-
sions [58, 59, 61].
The clinical phenotype of C9ORF72-related FTLD has 
also been compared to FTLD cases carrying mutations 
in GRN and MAPT. In an early study, no clinical differ-
ences were seen between C9ORF72, GRN and MAPT 
cases, although neuroimaging showed predominant fron-
tal atrophy was more common in the C9ORF72-related 
cases. A subsequent study showed that the C9ORF72-
related FTLD cases showed an earlier age of onset than 
GRN mutation carriers, whilst survival was similar, 
and whereas bvFTLD was most commonly associated 
with C9ORF72 expansions, PNFA was more commonly 
associated with GRN mutations [60]. Within a cohort of 
bvFTLD the relative frequencies of these three genetic 
variants showed that in familial cases, the frequency 
of C9ORF72 was similar to MAPT mutations (14.7 and 
12.7 %, respectively) but GRN mutations were of lower 
frequency (6.8 %) [35]. In sporadic bvFTLD cases, how-
ever, the frequency of these three mutations in the cohort 
was similar, at 3–4 %.
Other dementia and psychosis-related phenotypes
Alzheimer’s disease
Initial screening of Alzheimer’s disease (AD) patients 
either failed to find any C9ORF72 expansions or suggested 
that the cases were misdiagnosed FTLD cases [5, 47, 62]. 
Indeed, pathological studies of these initial Alzheimer’s 
disease cases identified none of the p62-positive inclusions 
in hippocampus and cerebellum which are considered 
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pathognomonic for C9ORF72 disease [41, 63]. However, 
subsequent screening of AD cohorts has identified sev-
eral cases with C9ORF72 expansions, including individu-
als with autopsy confirmed AD [64–66]. The cases were 
also shown to carry the risk A-allele at rs389942. In addi-
tion, it was found that these C9ORF72-related AD cases 
have a later age of onset, at 77.8 years, compared to the 
rest of the cohort of over 1,000 definite or probable AD 
cases [66, 67]. However, no association of C9ORF72 with 
the APOE ε4 status was identified [65, 66]. Therefore, the 
C9ORF72 expansion is associated with AD at low fre-
quencies (<1 %), but notably more often than in healthy 
controls [64–66].
Other dementia‑related disorders screened or associated 
with for C9ORF72 expansions
Expansions of C9ORF72 have also been identified in sin-
gle cases of dementia with Lewy bodies [68] and sporadic 
Creutzfeldt–Jakob disease [1], although the former patient 
is proposed to suffer from a FTLD TDP-proteinopathy that 
mimics Lewy body dementia. Interestingly, whilst psycho-
sis is highly associated with C9ORF72-related bvFTLD, no 
C9ORF72 expansions were seen in a cohort of 192 schizo-
phrenia cases [69].
ALS–FTLD
ALS and FTLD have been linked both through fami-
lies presenting with ALS, FTLD or both diseases. It was 
through studying these families that the Chr9p21 locus 
and C9ORF72 as a genetic cause of ALS and FTLD was 
identified [2, 3]. Several other genes associated with ALS 
have subsequently been found, albeit less commonly, in 
FTLD (TARDBP, FUS) and vice versa (CHMP2B). How-
ever, C9ORF72 provides the strongest link between the 
two disorders. Whilst previously familial ALS or familial 
FTLD was classified if there was a close family mem-
ber with the disease, the incidence of familial disease 
increases if both ALS and dementia are included [4]. 
Screening of ALS–FTLD cases has shown that C9ORF72 
expansion is the most common cause of familial ALS–
FTLD, accounting for the majority (sometimes all) of the 
ALS–FTLD cases screened [25, 26, 56]. Individuals can 
present with ALS or FTLD first and then go on to develop 
the other disease manifestation later. Clinically and patho-
logically patients possess both classical ALS and FTLD 
symptoms and neuropathology. The molecular basis for 
this disease specification is currently unknown, although 
work is beginning to elucidate the effect of the expansion 
length and other genetic and environmental modifiers on 
C9ORF72 disease.
Clinical phenotype specification: role of expansion 
length
In a repeat expansion-related disorder the most obvious 
candidate for a genetic modifier is repeat number. Measure-
ment of the G4C2 repeat length initially proved technically 
challenging as it is not amenable to PCR-based sequencing. 
However, a number of groups have now optimised South-
ern hybridisation-based techniques [1, 70, 71] which allow 
sizing of the expansion. So far, in a pure ALS group, no 
aspect of phenotype has been shown to significantly corre-
late with the length of the expansion regardless of the tissue 
tested [71, 72]. However, in FTLD, van Blitterswijk et al. 
[71] revealed a direct correlation between repeat size in the 
frontal cortex and age of onset, and a threshold repeat size 
in the cerebellum associated with reduced survival. The 
work also established that the repeat length in the cerebel-
lum was shorter than in other CNS areas (mean of approxi-
mately 1,667 repeat units compared to approximately 5,250 
repeat units in the frontal cortex). It is hypothesised that 
repeat expansions can increase in size through a human 
lifetime resulting in significant somatic heterogeneity [73] 
and therefore, perhaps the minimum repeat length in the 
CNS is more reflective of the germline repeat number. If 
so, the expansion length in the cerebellum may best repre-
sent the repeat length which initiated the disease pathogen-
esis; and the correlation with age of onset in frontal cortex 
may simply reflect the patient’s age. In this context it is 
interesting, but not conclusive, to note that the same study 
found smaller repeat lengths in blood from two out of three 
unaffected expansion carriers compared to their affected 
relatives. A smaller study identified a positive correla-
tion between repeat length and age of onset in C9ORF72-
related patients with a variety of neurodegenerative pheno-
types including FTLD, ALS and Alzheimer’s disease [1] 
but as described above, this may simply reflect the individ-
ual’s age at the time of sampling. It has also been shown 
that the length of the non-expanded allele is not a disease 
modifier in C9ORF72-related or non-C9ORF72 ALS or 
FTLD [71, 74, 75].
One of the significant questions is whether there is evi-
dence of anticipation in C9ORF72-related disease. Benussi 
and colleagues [6] reported on C9ORF72-related FTLD 
families which showed evidence of anticipation with a 
mean difference in age of onset between the parent and off-
spring of 9.8 years; This was also seen by Chio et al. [76], 
with age of onset 7 years earlier in the subsequent genera-
tion in Italian ALS cases. However, whether this related to 
expansion size is still to be determined, perhaps through 
Southern blotting analysis of parents and offspring DNA.
In summary, a clear relationship between C9ORF72 
expansion size and disease severity has not yet been iden-
tified, particularly in ALS. Comparison with the literature 
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on myotonic dystrophy type I (DM1) is informative on this 
point. Similar to C9ORF72-related disease, DM1 is caused 
by a repeat expansion in a non-coding region of DMPK. 
In DM1, correlation between repeat size and phenotype is 
apparent, but only when a large number of cases (>100) 
are considered [77]. The reason for this is thought to be 
the presence of other disease modifiers, the effect of which 
must be averaged out before a genotype–phenotype corre-
lation is identifiable. Clinically this is relevant because it 
means that measurement of repeat length could never serve 
as a prognostic biomarker. As yet the studies of expansion 
length in C9ORF72-ALS have only included relatively 
small numbers of patients and so there is still a case to 
answer. Work on the pathogenic mechanism in C9ORF72 
disease appears to be settling on a gain-of-function toxic-
ity mediated either by RNA foci formed from the repeat 
sequence [2] or dipeptide repeat protein formed by repeat 
associated non-ATG (RAN) translation [78, 79]. Numbers 
of RNA foci have been correlated with pathogenic sever-
ity in cell models [80, 81], and in tissue from FTLD cases 
[82]. RAN-translated dipeptide repeat protein appears to be 
toxic in a cell model [83], but levels of the aberrantly trans-
lated protein observed do not correlate with neurodegenera-
tion in autopsy material [34]. If, as postulated, pathogenesis 
is mediated in a gain-of-function manner then expansion 
size would be expected to modify the disease phenotype 
(Fig. 2).
Other than disease severity it is also interesting to ask 
whether expansion size has an effect on perhaps the most 
noticeable source of variability in the C9ORF72 disease 
phenotypes: the primary group of neurons affected. Cur-
rently, work has been limited to comparing C9ORF72-
ALS and C9ORF72-FTLD cases. One study suggested that 
longer repeat sizes in blood are associated with ALS as 
opposed to FTLD [72], but others suggested that there is no 
difference between the two subtypes [1, 71]. However, the 
largest group size with a pure phenotype in either of these 
studies was 38 patients; larger numbers will be required to 
verify either conclusion.
Finally, the G4C2 expansions have been described as 
pathogenic if they are over 30 repeats. However, relatively 
small repeat sizes are reportedly pathogenic in FTLD 
[84] and the clinical phenotype of ALS cases with 20–30 
repeats are similar to those with over 30 repeats [85]. 
Therefore, the minimum number of repeats required for 
pathogenicity may be smaller than the currently adopted 
cut-off size of 30 repeats. If true, this has an impact on 
another hypothesised pathogenic mechanism in C9ORF72 
disease: haploinsufficiency. Reduced expression of 
C9ORF72 mRNA is seen in the presence of the expansion 
[2]. However, it has been demonstrated that small expan-
sions of approximately 50 repeats do not reduce tran-
scription [86] possibly because smaller expansions do not 
lead to hypermethylation of a CpG island 5′ to the repeat 
sequence [87]. If smaller repeat lengths are pathogenic, 
then haploinsufficiency is not the responsible mechanism. 
Another observation not consistent with haploinsuffi-
ciency comes from two patients with expansions of both 
C9ORF72 loci; one a homozygote [16] and the other a 
compound heterozygote [86]. Both cases suffered FTLD 
but neither phenotype was outside the usual phenotypic 
spectrum. This is not consistent with a pure haploinsuf-
ficiency model which would predict a disease severity in 
proportion to the number of involved alleles. It remains to 
be seen whether haploinsufficiency is a disease modifier, 
in particular we await the arrival of a specific antibody to 
accurately detect protein levels of C9ORF72, but evidence 
is growing that it cannot be the sole or even the primary 
mechanism in C9ORF72 disease (Fig. 2).
Expansion Length
C9ORF72 
Transcription
Reduced 
C9ORF72 Protein 
Function
3. RNA Foci
2. Dipeptide 
Repeat Protein 
1. Haploinsufficiency 
TMEM106B 
Genotype
Fig. 2  Proposed pathogenic mechanisms and modifiers in C9ORF72 
disease. Three prominent mechanisms of pathogenesis have been pro-
posed in C9ORF72 disease: (1) Haploinsufficiency, (2) RAN transla-
tion of the expansion to form dipeptide repeats and (3) the formation 
of toxic RNA foci. Poly-(Gly-Ala)- dipeptide repeat protein is shown 
(stained in green, arrowed) aggregated in the cytoplasm of a cerebel-
lar granule cell from a C9ORF72-ALS patient. RNA foci containing 
the G4C2 repeat sequence are shown (stained red, arrowed) within 
a fibroblast obtained from a C9ORF72-ALS patient. There is some 
evidence that the repeat length is a modifier of the disease phenotype 
which would be consistent with mechanisms (2) and (3). However, 
case reports suggest that disease phenotype is not directly propor-
tional to the number of affected alleles which goes against mecha-
nism (1). The function of the C9ORF72 protein is unknown, but a 
role in membrane trafficking has been proposed which is consistent 
with the modifier effect of the TMEM106B genotype: both C9ORF72 
and TMEM106B are postulated to be involved in lysosome function
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Clinical phenotype specification: other potential disease 
modifiers
The striking variability in the phenotype associated with 
the C9ORF72 expansion suggests that multiple modifiers 
may exist, which may be genetic or environmental. Each 
identified modifier is a potential therapeutic target and, 
therefore, understanding factors influencing the phenotype 
of C9ORF72 disease is likely to be an important avenue 
of research in the near future. In addition to the expansion 
length (described above), a number of other modifiers have 
been investigated, including TMEM106B genotype.
TMEM106B genotype
A genome-wide association study initially identified single 
nucleotide polymorphisms (SNPs) in TMEM106B as risk 
factors for FTLD with TDP-43 positive pathology (which is 
found in C9ORF72-related FTLD cases amongst other sub-
types) [88]. The protein product of TMEM106B is localised 
to the lysosome. Its function is as yet only beginning to be 
understood, but it has been suggested that the protective iso-
form is expressed at a lower level because of increased pro-
tein degradation mediated via altered glycosylation [89].
The haplotype associated with higher risk of FTLD-TDP, 
more particularly the major, or T, allele of rs1990622, has 
recently been investigated in the context of C9ORF72-related 
disease [90]. The major allele is significantly associated with 
FTLD presentations of C9ORF72-related disease and is asso-
ciated with an earlier age of onset in GRN-related FTLD. 
However, in C9ORF72-FTLD, the major allele is associated 
with a later age of onset and death. There is no effect on the 
phenotype in GRN-negative non-C9ORF72 FTLD-TDP 
patients. This fascinating complexity suggests an interaction 
between the C9ORF72 expansion and TMEM106B genotype 
and suggests both proteins may have similar function. Inter-
estingly, it has been suggested that the C9ORF72 protein is 
structurally associated with the DENN family of proteins [91] 
which are implicated in the regulation of membrane traffick-
ing required for lysosome function (Fig. 2).
Interestingly, in contrast to the C9ORF72-FTLD find-
ings; it has been shown that neither TMEM106B allele is 
significantly associated with a C9ORF72-related ALS pres-
entation [92]. Why the TMEM106B genotype modifies the 
risk of one phenotype and not the other is unknown, but 
this suggests that the mechanism of neurotoxicity may be 
different in each case.
Other modifiers
As mentioned above, we have suggested that multiple scle-
rosis influences the penetrance and phenotype of C9ORF72-
related ALS patients. Moreover, we showed that, in contrast 
to non-C9ORF72 ALS cases, C9ORF72-related ALS cases 
showed a reduction in CSF levels of the cytokine CXCL10 
[42] which is reportedly neuroprotective in ALS [93]. Neuro-
inflammation and activation of microglia have been detected 
pathologically [94] and in imaging studies [95] of ALS 
patients. It is thought that the activity of non-neuronal cells 
may be key determinants of disease propagation through the 
CNS [96], if not in disease initiation directly.
Conclusion
Identification of the C9ORF72 repeat expansion has estab-
lished the most common cause of ALS, FTLD and ALS–
FTLD. Recent screening of related clinical phenotypes 
has extended the disease spectrum in which the C9ORF72 
expansion is found, including Alzheimer’s disease and 
parkinsonism. As Southern blotting is used to more accu-
rately size the repeat in larger cohorts of cases, and in mul-
tiple tissues, correlations between the expansion length and 
clinical characteristics may be revealed. Finally, given the 
frequency of the expansion in both ALS and FTLD, this 
population will provide an ideal group to elucidate the role 
of genetic and environmental modifiers contributing to the 
heterogeneity of disease.
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